Literature DB >> 23148574

The 60-day temperature-dependent degradation of midazolam and Lorazepam in the prehospital environment.

Jason T McMullan1, Ashley Pinnawin, Elizabeth Jones, Kurt Denninghoff, Nicholas Siewart, Daniel W Spaite, Erin Zaleski, Robert Silbergleit.   

Abstract

BACKGROUND: The choice of the optimal benzodiazepine to treat prehospital status epilepticus is unclear. Lorazepam is preferred in the emergency department, but concerns about nonrefrigerated storage limits emergency medical services (EMS) use. Midazolam is increasingly popular, but its heat stability is undocumented.
OBJECTIVE: This study evaluated temperature-dependent degradation of lorazepam and midazolam after 60 days in the EMS environment.
METHODS: Lorazepam or midazolam samples were collected prior to (n = 139) or after (n = 229) 60 days of EMS deployment during spring-summer months in 14 metropolitan areas across the United States. Medications were stored in study boxes that logged temperature every minute and were stored in EMS units per local agency policy. Mean kinetic temperature (MKT) exposure was derived for each sample. Drug concentrations were determined in a central laboratory by high-performance liquid chromatography. Concentration as a function of MKT was analyzed by linear regression.
RESULTS: Prior to deployment, measured concentrations of both benzodiazepines were 1.0 relative to labeled concentration. After 60 days, midazolam showed no degradation (mean relative concentration 1.00, 95% confidence interval [CI] 1.00-1.00) and was stable across temperature exposures (adjusted R(2) -0.008). Lorazepam experienced little degradation (mean relative concentration 0.99, 95% CI 0.98-0.99), but degradation was correlated to increasing MKT (adjusted R(2) 0.278). The difference between the temperature dependence of degradation of midazolam and lorazepam was statistically significant (T = -5.172, p < 0.001).
CONCLUSIONS: Lorazepam experiences small but statistically significant temperature-dependent degradation after 60 days in the EMS environment. Additional study is needed to evaluate whether clinically significant deterioration occurs after 60 days. Midazolam shows no degradation over this duration, even in high-heat conditions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23148574      PMCID: PMC4111795          DOI: 10.3109/10903127.2012.722177

Source DB:  PubMed          Journal:  Prehosp Emerg Care        ISSN: 1090-3127            Impact factor:   3.077


  8 in total

Review 1.  Out-of-hospital medication storage temperatures: a review of the literature and directions for the future.

Authors:  Lawrence H Brown; Kurt Krumperman; Christopher J Fullagar
Journal:  Prehosp Emerg Care       Date:  2004 Apr-Jun       Impact factor: 3.077

2.  Review: Lorazepam provides the best control for status epilepticus.

Authors:  J Craig Henry; Robert Holloway
Journal:  ACP J Club       Date:  2006 Mar-Apr

3.  Prehospital stability of diazepam and lorazepam.

Authors:  M D Gottwald; L C Akers; P K Liu; P J Orsulak; M D Corry; P Bacchetti; S M Fields; D H Lowenstein; B K Alldredge
Journal:  Am J Emerg Med       Date:  1999-07       Impact factor: 2.469

4.  Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis.

Authors:  Jason McMullan; Comilla Sasson; Arthur Pancioli; Robert Silbergleit
Journal:  Acad Emerg Med       Date:  2010-06       Impact factor: 3.451

5.  A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus.

Authors:  B K Alldredge; A M Gelb; S M Isaacs; M D Corry; F Allen; S Ulrich; M D Gottwald; N O'Neil; J M Neuhaus; M R Segal; D H Lowenstein
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

6.  Intramuscular versus intravenous therapy for prehospital status epilepticus.

Authors:  Robert Silbergleit; Valerie Durkalski; Daniel Lowenstein; Robin Conwit; Arthur Pancioli; Yuko Palesch; William Barsan
Journal:  N Engl J Med       Date:  2012-02-16       Impact factor: 91.245

7.  Stability of advanced life support drugs in the field.

Authors:  Mark A Gill; Alice Z Kislik; Lana Gore; Angela Chandna
Journal:  Am J Health Syst Pharm       Date:  2004-03-15       Impact factor: 2.637

Review 8.  New anticonvulsant drugs. Focus on flunarizine, fosphenytoin, midazolam and stiripentol.

Authors:  M Bebin; T P Bleck
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

  8 in total
  6 in total

1.  Lessons from the RAMPART study--and which is the best route of administration of benzodiazepines in status epilepticus.

Authors:  Robert Silbergleit; Daniel Lowenstein; Valerie Durkalski; Robin Conwit
Journal:  Epilepsia       Date:  2013-09       Impact factor: 5.864

2.  Pediatric respiratory distress: California out-of-hospital protocols and evidence-based recommendations.

Authors:  Tabitha Cheng; Jennifer Farah; Nicholas Aldridge; Sharon Tamir; J Joelle Donofrio-Odmann
Journal:  J Am Coll Emerg Physicians Open       Date:  2020-06-08

3.  Degradation of benzodiazepines after 120 days of EMS deployment.

Authors:  Jason T McMullan; Elizabeth Jones; Bruce Barnhart; Kurt Denninghoff; Daniel Spaite; Erin Zaleski; Robert Silbergleit
Journal:  Prehosp Emerg Care       Date:  2014-02-18       Impact factor: 3.077

4.  Temperatures of storage areas in large animal veterinary practice vehicles in the summer and comparison with drug manufacturers' storage recommendations.

Authors:  Jeff D Ondrak; Meredyth L Jones; Virginia R Fajt
Journal:  BMC Vet Res       Date:  2015-10-01       Impact factor: 2.741

Review 5.  Practical Management of Epileptic Seizures and Status Epilepticus in Adult Palliative Care Patients.

Authors:  Wenke Grönheit; Stoyan Popkirov; Tim Wehner; Uwe Schlegel; Jörg Wellmer
Journal:  Front Neurol       Date:  2018-08-02       Impact factor: 4.003

6.  Prehospital Care for the Adult and Pediatric Seizure Patient: Current Evidence-based Recommendations.

Authors:  Eric C Silverman; Karl A Sporer; Justin M Lemieux; John F Brown; Kristi L Koenig; Marianne Gausche-Hill; Eric M Rudnick; Angelo A Salvucci; Greg H Gilbert
Journal:  West J Emerg Med       Date:  2017-03-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.